Answers are grounded in this paper and cite their sources.
OBJECTIVE: Our objective was to assess the prevalence and incidence of autoimmune diseases (ADs) in a cohort of patients with anti-phospholipid syndrome (APS) in Stockholm Region, compared with the general population. The impact of a high-risk anti-phospholipid antibody profile, defined as triple positivity, was examined. METHOD: In this retrospective cohort study, 250 patients with APS followed at Karolinska University Hospital, Stockholm, from 2014 to 2020 were included through medical record review. ADs were classified as rheumatic (RADs) or non-rheumatic (NRADs) using ICD-10 codes. Logistic regression was used to estimate adjusted odds ratios (aORs) for ADs associated with patient characteristics at the start of follow-up. Population comparators (5:1 ratio) were matched by birth year, sex, and area of residence. Incidence rate ratios (IRRs) were estimated by Poisson regression with 95% confidence intervals (CIs). RESULTS: Among the cohort (68% women, median age 45 years, interquartile range 35-59 years), 127 patients had ADs at the start of follow-up. The prevalence of AD was 51%; 96 (38%) had a RAD and 55 (22%) an NRAD. Triple positivity was present in 48% of patients and was associated with increased odds of AD (aOR1.6, 95% CI 0.95-2.6). During follow-up, all patients with APS had a significantly higher incidence of new ADs compared with population comparators (IRR 7.5, 95% CI 4.4-13.0). There was a high incidence of new ADs in triple-positive patients (IRR 8.3, 95% CI 4.1-16.7). CONCLUSION: Patients with APS, particularly those with triple-positive antibodies, exhibit high autoimmune comorbidity, supporting the need for careful longitudinal follow-up.
No takes yet. Share an insight, caveat, or question.
Karandyszowska et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: